Approved for Chronic Weight Management

In studies with BELVIQ® 10 mg Twice Daily

Proven Weight Loss With Lasting Impact


Patients treated with BELVIQ® were 3 to 4 times more likely to achieve 10% weight loss vs. placebo in studies of more than 6600 patients1.

  • Pooled BLOOM/BLOSSOM: OR 3.1 (95% CI: 2.6, 3.6); 22.4% taking BELVIQ® vs 8.7% taking placebo, P<.001
  • BLOOM DM: OR 4.1 (95% CI: 2.1, 8.1); 16.3% taking BELVIQ® vs 4.4% taking placebo, P<.001
Pooled 1-Year Efficacy Results in Patients Without Diabetes >

CI=confidence interval; OR=odds ratio

Long-Term Results

Two-thirds of patients who continued taking BELVIQ® beyond Year 1 maintained clinically meaningful weight loss through Year 2

BLOOM 2-Year Data >

Change in Multiple Cardiometabolic Parameters

  • BELVIQ® demonstrated a decrease in blood pressure and heart rate*1,2
    • Blood pressure: –1.8/–1.6 mmHg with BELVIQ® vs –1.0/–1.0 mmHg with placebo (systolic/diastolic)
    • Heart rate: –1.2 bpm with BELVIQ® vs –0.4 bpm with placebo
    • Because BELVIQ®/BELVIQ XR® may cause a slow heartbeat, it should be used with caution in patients with a history of bradycardia or heart block greater than first degree
  • Patients taking BELVIQ® demonstrated significant reductions in HbA1c and fasting plasma glucose*1,4
    • HbA1c: –0.9% with BELVIQ® vs –0.4% with placebo
    • Fasting plasma glucose: –27.4 mg/dL with BELVIQ® vs –11.9 mg/dL with placebo
  • Belviq is not indicated for the treatment of blood pressure, heart rate, or type 2 diabetes.

*The effect of BELVIQ® on cardiovascular morbidity and mortality has not been established.

Impact on BP, HR, and Other Cardiometabolic Parameters >

HbA1c=hemoglobin A1c.

Safety and Tolerability

  • The most common adverse reactions for BELVIQ® 10 mg twice daily
    • In patients without diabetes: headache (17%), dizziness (9%), fatigue (7%), nausea (8%), dry mouth (5%), and constipation (6%)
    • In patients with diabetes: hypoglycemia (29%), headache (15%), back pain (12%), cough (8%), and fatigue (7%)
  • Discontinuation rates due to adverse reactions were similar between BELVIQ® and placebo (8.6% vs 6.7%)
Safety and Tolerability >

Also Available - BELVIQ XR®: Simple, Once-Daily Formulation, Taken With or Without Food

BELVIQ is also available as a simple, once-daily formulation proven to be slowly absorbed in the body and last throughout the day. Bioequivalence was demonstrated between 20 mg, once-daily XR formulation and 10 mg, twice-daily dosing for BELVIQ.

Dosing & Administration > 

More About BELVIQ XR®

In 2016, the U.S. Food and Drug Administration (FDA) approved BELVIQ XR, an extended-release formulation of lorcaserin. BELVIQ XR offers simple, once-daily dosing for your patients, and can be taken with or without food.

In a phase 1 clinical trial,* BELVIQ XR extended-release, 20 mg tablets administered once daily were compared with the immediate-release formulation of BELVIQ 10 mg tablets administered twice daily and were found to be bioequivalent.3

  • A single-dose administration of BELVIQ XR 20 mg once daily, resulted in comparable total plasma exposure (AUC), but approximately 25% lower peak exposure (Cmax) relative to two doses of BELVIQ immediate release, 10 mg, twice daily
  • At steady state, Cmax and AUC of BELVIQ XR 20 mg once daily were determined to be bioequivalent to BELVIQ immediate-release 10 mg twice daily

Effect of food: There was no significant food effect on the rate or extent of absorption of BELVIQ XR.

*in 34 healthy patients


BELVIQ/BELVIQ XR is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes).

Limitations of Use:

  • The safety and efficacy of coadministration of BELVIQ/BELVIQ XR with other products intended for weight loss, including prescription drugs (e.g., phentermine), over-the-counter drugs, and herbal preparations, have not been established.
  • The effect of BELVIQ/BELVIQ XR on cardiovascular morbidity and mortality has not been established.



  • Pregnancy: BELVIQ/BELVIQ XR should not be taken during pregnancy or by women who are planning to become pregnant.
  • Hypersensitivity: Patients with prior hypersensitivity reactions to lorcaserin or to any of the product components should not take BELVIQ/BELVIQ XR. Hypersensitivity reactions have been reported.

Warnings and Precautions

  • Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)- like reactions: BELVIQ/BELVIQ XR is a serotonergic drug. The development of potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported during use of serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors, and selective serotonin reuptake inhibitors, tricyclic antidepressants, bupropion, triptans, dietary supplements such as St. John's Wort and tryptophan, drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors), dextromethorphan, lithium, tramadol, antipsychotics or other dopamine antagonists, particularly when used in combination. Patients should be monitored for the emergence of serotonin syndrome symptoms or NMS-like reactions, including agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, nausea, vomiting, diarrhea, and muscle rigidity. Treatment with BELVIQ/BELVIQ XR and any concomitant serotonergic or antidopaminergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
  • Valvular heart disease: Patients should not take BELVIQ/BELVIQ XR in combination with potent 5-HT2B receptor agonists that have been associated with regurgitant valvular heart disease (e.g., cabergoline). In clinical trials, 2.4% of patients taking BELVIQ and 2.0% of patients taking placebo developed valvular regurgitation: none of these patients were symptomatic. BELVIQ/BELVIQ XR should be used with caution in patients with congestive heart failure (CHF). Patients who develop signs and symptoms of valvular heart disease, including dyspnea, dependent edema, CHF, or a new cardiac murmur, should be evaluated and discontinuation of BELVIQ/BELVIQ XR should be considered.
  • Cognitive impairment: Impairment in attention, memory, somnolence, confusion, and fatigue have been reported in patients taking BELVIQ. Patients should not drive a car or operate heavy machinery until they know how BELVIQ/BELVIQ XR affects them.
  • Psychiatric disorders: The recommended daily dose should not be exceeded, as higher doses may cause euphoria, hallucination, and dissociation. Monitor patients for the development or worsening of depression, suicidal thoughts or behaviors, and/or any changes in mood. Discontinue BELVIQ/BELVIQ XR in patients who develop suicidal thoughts or behaviors.
  • Hypoglycemia: Weight loss may increase the risk of hypoglycemia in patients with type 2 diabetes mellitus who are being treated with antidiabetic medications, so measurement of blood sugar levels before and during treatment with BELVIQ/BELVIQ XR is recommended. Decreases in doses of antidiabetic medications or changes in medication regimen should be considered.
  • Priapism: Men who experience priapism should immediately discontinue BELVIQ/BELVIQ XR and seek emergency medical attention. BELVIQ/BELVIQ XR should be used with caution with erectile dysfunction medications. BELVIQ/BELVIQ XR should be used with caution in men who have conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or in men with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie's disease).
  • Heart rate decreases: Because BELVIQ/BELVIQ XR may cause a slow heartbeat, it should be used with caution in patients with a history of bradycardia or heart block greater than first degree.
  • Monitoring Considerations: Consider monitoring for CBC changes, signs and symptoms of prolactin excess, and pulmonary hypertension.

Most Common Adverse Reactions for BELVIQ®

  • In patients without diabetes: headache (17%), dizziness (9%), fatigue (7%), nausea (8%), dry mouth (5%), and constipation (6%).
  • In patients with diabetes: hypoglycemia (29%), headache (15%), back pain (12%), cough (8%), and fatigue (7%).

Most Common Adverse Reactions for BELVIQ XR®

  • Common side effects in patients on BELVIQ XR were similar to those seen in patients on BELVIQ.

Nursing Mothers

  • BELVIQ/BELVIQ XR should not be taken by women who are nursing.

BELVIQ®/BELVIQ XR® is a federally controlled substance (CIV) because it may be abused or lead to dependence.
For more information about BELVIQ®/BELVIQ XR®, see full Prescribing Information.